Hbabi-Haddioui L, Roques C
Faculté des Sciences Pharmaceutiques, Laboratoire de Bactériologie, Virologie et Microbiologie Industrielle, Toulouse, France.
Drugs. 1997;54 Suppl 1:29-32. doi: 10.2165/00003495-199700541-00008.
Oral 'Ribomunyl' has been shown to increase levels of specific salivary IgA. The ability of specific salivary IgA to inhibit the adhesion of Streptococcus pneumoniae to buccal epithelial cells was investigated in vitro using 13 saliva samples from healthy volunteers who received 'Ribomunyl' therapy for 3 weeks. The S. pneumoniae strain contained in 'Ribomunyl' was [3H]thymidine-labelled and pretreated with dilutions of saliva for 1 hour at 37 degrees C. Bacterial adhesion was measured after 2 hours' contact with human oral epidermal cell monolayers at 37 degrees C under CO2. Nonadherent bacteria were washed off, and the residual radio-activity of the monolayers was compared with that of bacteria not pretreated with saliva. A significant decrease (p < 0.05) in S. pneumoniae adhesion was observed with 6 saliva samples with high levels of specific IgA. This decrease was seen at all dilutions from 1/5 to 1/1000. In contrast, no significant modification of adhesion was seen in the 7 saliva samples with unmodified levels of IgA. These data demonstrate that the increase in salivary IgA levels during 'Ribomunyl' therapy was linked with the capacity of saliva samples to specifically and efficiently inhibit adhesion of S. pneumoniae to buccal epithelial cells in vitro.
口服“力保美达”已被证明可提高唾液中特异性免疫球蛋白A（IgA）的水平。本研究使用了13名健康志愿者的唾液样本，这些志愿者接受了为期3周的“力保美达”治疗，旨在体外研究特异性唾液IgA抑制肺炎链球菌黏附于颊黏膜上皮细胞的能力。将“力保美达”中含有的肺炎链球菌菌株用[3H]胸腺嘧啶核苷标记，并用不同稀释度的唾液在37℃下预处理1小时。在37℃、CO2环境下，使其与人口腔表皮细胞单层接触2小时后，测量细菌黏附情况。洗去未黏附的细菌，将细胞单层的残余放射性与未用唾液预处理的细菌的放射性进行比较。在6份特异性IgA水平较高的唾液样本中，观察到肺炎链球菌黏附显著减少（p<0.05）。在1/5至1/1000的所有稀释度下均可见这种减少。相比之下，在7份IgA水平未改变的唾液样本中，未观察到黏附的显著变化。这些数据表明，“力保美达”治疗期间唾液IgA水平的升高与唾液样本在体外特异性、高效抑制肺炎链球菌黏附于颊黏膜上皮细胞的能力相关。
